| Filed On | Filing |
|---|---|
| 12 Nov 2026 |
Form 4: Frates James M, Chief Financial Officer
Received 20,000 shares by exercise or conversion ($138K) · Sold 20,000 shares ($597K) · Received 20,000 shares by exercise or conversion ($138K) · 1 more |
| 12 Nov 2026 |
Form 4: Klee Justin B., Director
Sold 100,000 shares ($2.98M) |
| 12 Nov 2026 |
Form 4: Cohen Joshua B, Director
Sold 100,000 shares ($2.98M) |
| 09 Nov 2026 | 144 |
| 09 Nov 2026 | 144 |
| 09 Nov 2026 | 144 |
| 05 Nov 2026 | 10-Q |
| 05 Nov 2026 |
8-K: Results of Operations and Financial Condition
Reported positive topline results from Phase 3 LUCIDITY clinical trial of avexitide in post-bariatric hypoglycemia; New Drug Application submission planned by end of 2026 remains on track |
| 07 Oct 2026 |
Form 4: Milne George M Jr, Director
Sold 30,000 shares ($831K) |
| 05 Oct 2026 | 144 |
| 14 Sep 2026 |
Form 4: Bedrosian Camille L, Chief Medical Officer
Sold 10,028 shares ($325K) |
| 14 Sep 2026 |
Form 4: Frates James M, Chief Financial Officer
Sold 10,810 shares ($350K) |
| 14 Sep 2026 |
Form 4: Mazzariello Gina, Chief Legal Officer
Sold 9,536 shares ($310K) |
| 14 Sep 2026 |
Form 4: Klee Justin B., Director
Sold 30,464 shares ($980K) |
| 14 Sep 2026 |
Form 4: Cohen Joshua B, Director
Sold 30,464 shares ($981K) |
| 11 Sep 2026 | 144 |
| 11 Sep 2026 | 144 |
| 11 Sep 2026 | 144 |
| 11 Sep 2026 | 144 |
| 11 Sep 2026 | 144 |
Loading...